Hooper swaps BMS for Amgen

by emma 21. October 2011 12:31

Pf Industry News

Amgen has appointed Tony Hooper as its new Executive Vice President of Global Commercial Operations.

The 56-year-old joins from Bristol-Myers Squibb and will take on the responsibility for the companies commercial operations around the globe.

Robert Bradway, President and Chief Operating Officer, says Mr Hooper’s “passion for serving patients across the globe make him an outstanding addition”.

He joins after 16 years at BMS where he led the commercial business in the US, Asia, Middle East, Africa, South America and Europe. Most recently he served as the Senior Vice President, Commercial Operations and President, United States, Japan and Intercontinental.

“It's a privilege to join Amgen, a Company well-known for scientific innovation and developing life-changing therapies for people with serious illnesses,” said Mr Hooper. “I am looking forward to bringing my global commercial experience to Amgen as it moves to implement its strategic vision for growth and international expansion.”

On the same day at Hooper’s appointment, Amgen decided to cut 380 R&D jobs.

Aircraft Medical gains distribution deal with Covidien

by emma 12. October 2011 16:44

McGrath MAC

Scottish medtech company Aircraft Medical has signed an exclusive INTERNATIONAL distribution agreement with global healthcare supplier Covidien.

Covidien will market and distribute Aircraft’s McGRATH MAC video laryngoscope (pictured) in the UK, the US, Japan, Latin America, Australia and New Zealand.

The new agreement complements Aircraft Medical’s existing distribution agreements in 35 countries, and will see the number of specialist sales and marketing professionals selling the McGRATH laryngoscope worldwide rise above 500.

Launched in October 2010, the portable McGRATH MAC – a development of the award-winning McGRATH design – is the first low-cost video laryngoscope designed to assist both routine and difficult airway intubation in hospitals.

In the US, the majority of the estimated 17 million intubations carried out each year are performed with Covidien products – opening a major market opportunity for the McGRATH MAC.

About 50 million intubation procedures take place globally each year, and that figure is predicted to rise by 5% per year.

“This agreement with Covidien is a significant step forward in the global rollout of the McGRATH MAC video laryngoscope,” said Matt McGrath, CEO of Aircraft Medical. “We expect to now further strengthen our position in the growing video laryngoscope market.”

James E. Willett, General Manager, Respiratory and Monitoring Solutions at Covidien, commented: “Our partnership with Aircraft Medical demonstrates our commitment to deliver clinical value and improve patient outcomes in fast-growing critical-care markets throughout the world.

“By integrating the McGRATH MAC video laryngoscope into our respiratory product portfolio, Covidien can provide critical-care practitioners with a complete intubation solution to meet the needs of the continuum of patients.”

Aircraft Medical, based in Edinburgh, specialises in video laryngoscopes.

Covidien, based in Dublin, is a leading global provider of healthcare products whose 2010 revenue was $10.4 billion.

A winning formula

by emma 7. October 2011 15:00

A winning formula

In the pharmaceutical industry one of the biggest challenges is to manage large events which require certain levels of privacy, whilst also ensuring they are hosted in professional and accessible venues. Simon Hunter shares his knowledge on how to make the most of your venue and event.

A high profile venue is a prominent, well known, iconic space which has a range of facilities to offer, and a reputation for hosting annual industry exhibitions or summits for international brands.

Discretion and privacy are key attributes of hosting events at high profile venues. If there are well-known guests present or sensitive intellectual property being shared – a new scientific discovery or drug, for example, then this kind of venue is ideal.

 

Experience pays

Other advantages of high profile venues include a proven track record in hosting different sizes of events in-house. For example, Chelsea Football Club manages fixtures attracting 42,000 guests who need to be managed onsite and this translates to the events team and experienced in-house security. The higher profile the venue or the bigger the event brand, the more strategies will already be in place which can help.

With regards to security, trust the staff and the in-house teams; they will have the benefit of experience organising private events, managing arrangements for high profile guests, and advising on the best way to utilise facilities. A good venue will take you through all stages of the event and should ask in advance of any special requirements, schedules or VIP attendees.

Ensure that all channels of communication are left open during the event itself so that staff  know of any last minute alterations. This will also guarantee that event organisers look professional, with the additional help of the venue’s catering, service and after-care.

 

Deciding outcomes

Knowing your audience and the objectives you want to achieve from any event will be a great help in selecting a venue. It is therefore vital to outline these clearly before approaching any venues for suggested briefs. Following this, there are some useful points to bear in mind which will make selecting a suitable venue easier.

Consider the components of your event to make sure you select somewhere that can accommodate them all. For example, consider whether the event will be an annual conference with a gala dinner and accommodation; whether you need separate facilities for VIP guests; and the possibility of needing to bring in equipment for demonstrations or exhibitions.

Venues which offer numerous events spaces, like a music venue, accommodation, restaurants and an exclusive spa can be ideal for organisers wishing to combine many activities within one event. It will also reduce the need for a separate transport budget to transfer guests from between conferences and seminars, for example.

Every event organiser should be constantly focussed on how to get maximum results for minimum cost. Look for a venue that whilst impressive, offers a range of packages and choose the one that suits your audience and your budget.

 

Simon Hunter Simon Hunter is the Head of Venue at Chelsea Football Club.

Takeda completes Nycomed deal

by emma 3. October 2011 10:36

Pf industry news

Takeda Pharmaceutical Company has acquired Nycomed in a deal worth €9.6 million on a cash-free, debt-free basis.

The combined company will be commercially active in the therapeutic areas of metabolic diseases, gastroenterology, oncology, cardiovascular health, CNS diseases, inflammatory and immune disorders, respiratory diseases and pain management.

Current Takeda Executive Vice President of International Operations, Dr Frank Morich, has been appointed as CEO of Nycomed.

Yasuchika Hasegawa, President and CEO of Takeda, said: “Partnering the two organisations will have complementary effects and further increase our potential to become a truly global pharmaceutical company.”

Dr Morich said that the combined company’s pharmaceutical market will cover more than 70 countries, with a presence in Japan, North America, Europe and Asia.

“I look forward to bringing Takeda and Nycomed together to ensure we can achieve enhanced revenue, growth and diversification, while maintaining the strong momentum of both companies,” he said.

New PhRMA Board Director

by emma 23. September 2011 14:50

Pf industry news

Ikaria’s Chairman and CEO Daniel Tasse has been elected to the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA).

He joins the 31-person team and brings with him a wealth of experience and passion for critical care after formerly serving in managerial positions at GSK and Baxter International.

Mr Tasse says he is “honoured to join this prestigious group of industry leaders and innovators”.

In additional to his position on the board, he will also serve on the PhRMA Rare Disease and Emerging Company Committees.

“Through my new position on PhRMA's Board of Directors, I look forward to helping to move forward policies that will advance the pharmaceutical industry and continue to benefit patients during this important time for our industry and our economy,” said Mr Tasse.

He also serves as a member Board of Directors and Health Section Governing Board of the Biotechnology Industry Organization, is a member of the Healthcare Leadership Council and a Board Director of the Roundtable on Critical Care Policy.

Pharma must get in the ‘real world’ to prove value of medicines

by emma 22. September 2011 17:00

Pf industry news

The pharmaceutical industry is entering a ‘prove it works’ era that will rely increasingly on collaboration and partnership with the NHS, the ABPI has said.

Its new CEO, Stephen Whitehead, has said that the industry’s imperative to demonstrate the value of its medicines will rely on developing and using ‘real world data’.

But observers have warned pharma companies that if they want to use real word data, they must first ensure they ask customers ‘real world questions’, rather than rush out to provide data that suits their own agendas.

In his first address since becoming CEO, Whitehead said that for working partnerships to progress, the industry must show it is ‘part of the solution, not the problem’.

“For a number of years, the industry has worked in partnership with parts of the NHS to help redesign pathways,” he said. “We have moved beyond purchaser and seller transactional relationships; this next era will be based on partnerships and collaboration. And by using real world data we can, for the first time, provide evidence of value – we can prove it works.”

In line with this, the ABPI has published ‘The Vision for Real World Data – Harnessing the Opportunities in the UK’, which outlines how the UK industry can become a centre of excellence for the collection and analysis of Real World data (RW). It defines RW as data “that are collected outside the normal constraints of conventional randomised clinical trials to evaluate what is happening in normal clinical practice.”

The ABPI says that the collection of such data will lead to a better understanding of conditions and treatments in a wider population, help improve the management of chronic conditions, and the avoidance of preventable hospitalizations.

“Real World data will provide us with the means for assessing the true value of a medicine – it will provide us with the opportunity to improve patient quality of life while reducing NHS costs,” said Whitehead. “But to make the best possible use of Real World data we must have seamless collaboration between the NHS and the industry.”

The ABPI report makes a number of recommendations as to how the industry can make the transition towards RW data collection. These include the development of a toolkit for companies to present the case to global colleagues, and the need to engage at local, national and European level to streamline the regulatory environment for the conduct of RW data studies.

It also advocates increasing efforts to facilitate NHS partnerships with the industry in the collection and interpretation of RW data and further engagement with the wider medical community to ensure it is published in respected medical journals alongside traditional clinical trial findings.

The push for more Real World thinking has been widely applauded, but some commentators believe that much of what is needed to propel the new approach is already present in the system.

Andy Lee, Commissioning and NHS Partnerships Director, WG Group, said: “A lot of the data for RW studies is already there, it just needs a systematic approach to joining it up. The most important issue, however, is to demonstrate true partnership, not pay lip-service to it: if pharma is going to use real world data, it needs to make sure it asks the real world questions – and those are the questions that commissioners and medicines management leads will be asking, not necessarily those that pharma companies might like to try to prove. The two sides need to talk and agree the outcomes data that will really enable decisions to be made, and changes to actually happen.”

Low-profile balloon catheter for PAD launched

by emma 21. September 2011 13:54

Coyote Balloon Catheter

Boston Scientific has launched its new balloon dilation catheter, Coyote, to treat patients undergoing peripheral angioplasty procedures below the knee.

The Coyote Balloon Catheter is intended to help physicians when treating patients who have challenging obstructive lesions in the lower extremities.

With an ultra-low profile of 0.0174 inches, it promises to be highly deliverable and offer rapid deflation.

Balloon catheters are often used during peripheral angioplasty and stenting procedures to open blocked arteries.

J. A. Mustapha, Director of Endovascular Intervention at Metro Health Hospital in Wyoming, Michigan, said: “Its performance gives me greater confidence in being able to effectively treat patients with difficult anatomy who suffer from peripheral artery disease.”

The device is the latest in a series of balloon catheter products developed by Boston Scientific.  In June, the company launched its Mustang PTA Balloon Catheter, a 0.035 inch percutaneous transluminal angioplasty (PTA) catheter designed to be used in a range of peripheral angioplasty procedures.

Jeff Mirviss, President of Boston Scientific's Peripheral Interventions Division, said the new product launch “builds on Boston Scientific's global leadership in low-profile peripheral balloon angioplasty”.

Up to 9 million US patients suffer from peripheral artery disease, which is associated with high rates of morbidity.

Boston Scientific has begun marketing the product in the US, Europe and other international markets.

Orexo appoints new CCO

by emma 19. September 2011 10:46

Pf industry news

Orexo AB has appointed Nikolaj Sørensen as its new Chief Commercial Officer.

He will be responsible for commercial operations, as well as development of the company’s commercial strategies, and brings a wealth of international commercial experience.

Anders Lundström, President and CEO of Orexo AB, says the company is “particularly pleased” to recruit Mr Sørensen whose “background suits the company’s strategy”.

Mr Sørensen has previously worked at Pfizer where he was a Director and Brand Team Leader for pain treatment product in Europe and Canada. He also worked as Head of Business Development and Director of Strategic Planning, plus Business Area Director for primary care products, and as Managing Director and Chairman of the board for Pfizer AB.

For the past few years, he has also been a member of the Board of the Swedish Pharmaceutical Industry Association (LIF).

The company currently has four commercialised products and several projects developed in partnership, plus three further proprietary development programs. Its new Chief Commercial Officer says he has followed the progress of the company for a number of years.

“Orexo is an exciting company that I have followed for several years,” said Mr Sørensen. “The company has a very interesting product portfolio that provides a solid foundation for a commercial organisation. I look forward to developing and executing Orexo’s strategy for sales and marketing of the company’s own products.”

He will commence his role on 1 October.

Guess who?

by emma 29. August 2011 16:50

guesswho

It would seem that there’s a job perfectly suited to match the personality of each of us. However, despite various tests and metrics introduced to discover what role best suits certain individuals, Ian McGarry reveals it’s not quite that simple.

The words ‘know thy self’ were reported to have been inscribed in the forecourt of the Temple of Apollo at Delphi. Attributed to the Greek philosopher Thales, this proclamation urged the ancient to develop a greater level of self reflection and insight. Despite our obvious similarities as humans we are temperamentally very dissimilar from each other.

Understanding why we are so different has, over the centuries, vexed the minds of philosophers, doctors and psychologists alike. One of the earliest attempts to account for behavioural differences dates back over two thousand years. Galen, a Roman physician, distinguished four temperaments; melancholic (sombre, unhappy), choleric (irritable and easily angered), phlegmatic (apathetic, sluggish) and sanguine (cheerful, optimistic) which he thought, incorrectly, provided an insight into how individuals should be treated medically. His theories still survive in various forms to this day, though thankfully not so much in medicine!

The temperamental differences that obsessed Galen are the basis of what we have come to term our ‘personalities’. Over time, there have been numerous attempts to theorise, define and measure these qualities. It is only in the last hundred years or so that we have developed the psychological and statistical tools to move beyond speculation and metaphysics into more scientifically quantifiable concepts.

What is personality?

Personality refers to those enduring characteristics and traits that enable a person to be recognised as a distinct individual. Although not the whole picture, psychologists generally agree that personality plays an important role in how people behave. Many would urge caution however in assuming that personality underscores all behaviour, and this is especially true concerning our ability to perform and achieve success.

Though we may broadly agree what personality means there are still plenty of differing approaches taken to both quantifying and measuring its specific facets. A cursory glance at all of the models available to psychologists and organisations reveals a plethora of different personality tests all claiming to highlight the most revealing components of who we are.

More often, psychologists and researchers rely on a five-factor model developed by Costa and McCrae. Often referred to as ‘the big five’, this is available as an assessment tool (NEO-PI-R). This evidence-based model maintains that all the various structures of personality can be represented across the following five dimensions:

fivedimension

In short, your personality can be successfully represented as a measure of the combination of, and the level at, which you score against each dimension. But, whilst interesting, does it actually tell us anything about our potential for success in life?

Personality at work

It may be easy to accept that certain personality types may fair better at jobs more than others. We even tend to stereotype some professions by personality attributes, for example, introverted accountants or extroverted sales people. Understanding personality in order to predict behaviour is an attractive idea for those interested in personality research. As you may imagine, ascertaining someone’s potential performance in a job is an extremely attractive proposition for employers who want to match the best people to their vacancies, or promote those they believe have the greatest potential for success.

There are numerous personality profile tools on the market and many of us will have some experience of these in our working lives. It would be rare to meet someone in the pharmaceutical industry for example who hadn’t undertaken a personality test at an assessment centre, as part of a job application, or a personal development program. The associated costs of employing the right people for a job can be potentially massive leading some firms to try a variety of measures, some unfounded – such as handwriting analysis – to sort the ‘wheat’ from the ‘cha­ ’.

If used wisely, robust personality profiles may contribute to an overall view of a candidate where other assessment methods have also been implemented. Personality measures are unlikely, however, to provide a definitive picture or an accurate prediction of a person’s potential performance.

Personality and performance

Whilst personality traits are useful ways of describing external behaviour, they are problematic if we are referring to stable internal causes of behaviour. Suggesting that a person is angry about something because they have low levels of agreeableness – an angry personality – is similar to proclaiming the sea is wet because it has the quality of wetness.

You may have experienced this misuse of personality concepts yourself if you have met someone excusing their own behaviour on the grounds they are a particular ‘social style’. Unfortunately, whilst this may seem a reasonable justification on the surface, it is a bit nonsensical. In a similar fashion to the example above, it is akin to proclaiming that their radiator is hot because it has the quality of heat.

With the exception of the trait ‘conscientiousness’, there seems to be no universal personality factors that can be used to predict with any accuracy measures of a person’s success at work.

In order to successfully link a personality trait to work performance we have to understand what performance actually means; this in its self is a difficult undertaking. While we can accurately say good performance in sales is about selling more products, it is much harder to delineate the component factors of good sales ability.

A list of sales competences may fail to take into account a host of additional factors that contribute to performance, for example:

  • Differing sales context
  • Differing demographic cultures
  • Personal issues
  • Motivational factors
  • Company culture

These can be just some of the significant variables influencing performance outcomes. Perhaps in the future ‘job performance’ will be better understood, enabling a clearer link to emerge with personality traits. But until then, assessing personality as a criterion for any prospective job performance will be more an art than a science.

A clear understanding

Despite the above caveats, learning about the diversity of personality types can be very useful for the development of teams and cross-functional groups. Learning to understand interpersonal di­fferences encourages people to widen their appraisals of other’s behaviour and what it may mean. This may potentially expand a group’s behavioural norms. For example, a manager I worked with described her team as an “up for it, go getting team…except Dave, who is quiet and thoughtful …but that’s ok, we realise he prefers to reflect and someone needs to….!”

Without this level of insight it is an easy step for a group unaware of their own dynamics to ostracise and exclude people whose personality style is even slightly at odds with the group norm. To avoid communication breakdown people need to be flexible to other’s ‘styles’.

This can ensure that people like ‘Dave’ have the necessary psychological space to contribute and grow in teams that may be composed of more extroverts. As well as helping us understand other’s diverse approaches to life, personality tools help us understand our own behaviour. “Oh wad some power the giftie gie us. To see oursel’s as others see us! It wad frae monie a blunder free us, And foolish notion,” Robert Burns.

As individuals we are often blind to certain aspects of our own style and the impact it can have on others. Using personality metrics to understand our own personality can be revealing and very helpful as we seek to follow the still relevant advice ‘know thy self’. Gauging the a­ffect you have on others from a different position can, as the poet Robbie Burns suggests in his oft quoted poem, save us from many a blunder.

Useful personality metrics

Whilst the amount of personality tests and systems available are far too numerous to cover in this article, most fall into one of two categories:

  • Normative tests: These involve measuring your relative score on separate traits and contrasting these against group norms, such as either the general population or specific group, for example NEO-PI-R.
  • Ipsative tests: These prompt you to make choices between di­fferent options on a questionnaire. They are mutually exclusive so that choosing one option prevents you choosing an alternative. When calculated a profile will emerge that places you into a predefined specific category and various social style systems which confer labels and types to people. When people complain or rejoice at being ‘pigeon holed’ it is often the Ipsative type test they have experienced.

Which tests work?

Well, that depends on what you want to do with the results. There are a lot to choose from. Profiles available through the British Psychological Society (BPS) registered psychometricians are likely to be evidence-based and robust enough to confer some useful insight. As mentioned earlier, there is a growing consensus amongst researchers that the big five as represented by the NEO-PI-R test capture real functional di­fferences in personality in a relatively straight forward way.

Additionally, some new developments in the realms of ‘emotional intelligence’, although controversial with some psychologists, can provide a di­fferent take on behaviour and these can prove useful, especially when considering team dynamics and interpersonal skills training. Emotional Behaviours at Work (EBW) is one example of this type of test.

In the end

It seems common sense that certain personality types are good at certain jobs. While there may be some broad truth to the idea that certain temperaments gravitate towards certain job types, in the main, personality tests are not currently reliable indicators of individual career performance or success. There are too many possible variables at play, both in the types of personality assessment used and the how we might define performance in any given context. Personality tests can be an excellent way to develop insight into your own behavioural tendencies and those of others. Thus helping foster better/more tolerant relationships and strengthen teamwork. So, if getting on with others is important to you and your work, knowing who you are does matter.

Ian McGarry is an international business psychologist. He can be contacted directly at mcgarry.ian92@gmail.com

Valeant appoints new board member

by emma 5. August 2011 14:24

Pf industry news

Valeant Pharmaceuticals International has appointed Ronald Farmer to its Board of Directors.

J. Michael Pearson, Chairman and CEO of Valeant, stated that it was a “privilege” to welcome Mr Farmer’s “unparalleled intellect and superior business judgment” to the Board.

Mr Farmer currently works as Managing Director of Mosaic Capital Partners in Toronto, Canada. He is also a Director at Integran Technologies, PowerMetal Technologies and Boatracs Inc.

Valeant Pharmaceuticals International is a global pharmaceutical company that develops, manufactures and markets pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.

TextBox

Tag cloud

RecentPosts

Calendar

<<  May 2013  >>
MoTuWeThFrSaSu
293012345
6789101112
13141516171819
20212223242526
272829303112
3456789

View posts in large calendar